Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mulberroside F is a natural small molecule compound isolated from the leaves, roots, and stem bark of the mulberry tree (*Morus alba* L.). Chemically identified as a moracin derivative (Moracin M-6), it primarily functions as a tyrosinase inhibitor, effectively suppressing melanin biosynthesis and formation. This activity has led to its investigation as a potential skin-whitening agent in cosmeceutical applications. Beyond its dermatological potential, mulberroside F exhibits antioxidant properties through superoxide scavenging and has demonstrated anti-inflammatory activity in animal models of asthma by inhibiting Th2-cell activation and reducing eosinophil infiltration. It is currently utilized as a research chemical and is not known to be in clinical development as a pharmaceutical drug by any specific company.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mulberroside F.